PLYMOUTH MEETING, Pa., Aug. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of INOVIO's management team will also be conducting in-person one-on-one meetings with investors.
H.C. Wainwright 27th Annual Global Investment Conference
Presentation available: Beginning Friday, September 5, 2025, 7:00AM ET
Format: Pre-recorded webcast
Link: https://journey.ct.events/view/c0cc4d12-f619-4d58-878f-4ee305e4f2c2
The webcast will be available for 90 days at the link above or on the INOVIO Investor Relations Events page: https://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$1.73 |
| Daily Change: | -0.56 -24.45 |
| Daily Volume: | 13,623,537 |
| Market Cap: | US$118.850M |
December 29, 2025 November 10, 2025 November 10, 2025 November 03, 2025 October 21, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load